


Rockford Pulmonary Clinic PLLC in Rockford, Illinois, operates under the medical direction of Dr. Tabassum Nafsi, MD, FCCP, a board-certified pulmonologist and Fellow of the American College of Chest Physicians. While the clinic's foundation remains comprehensive pulmonary medicine—treating asthma, chronic obstructive pulmonary disease, sleep apnea, and lung cancer—Dr. Nafsi has expanded services to include medically supervised weight loss programs utilizing GLP-1 receptor agonist peptides. This integration reflects the growing recognition that metabolic health directly impacts respiratory function, particularly in patients with obesity-related breathing disorders and sleep-disordered breathing.
The clinic prescribes both Semaglutide and Tirzepatide for weight management in appropriate candidates. Semaglutide, a GLP-1 agonist, works by mimicking incretin hormones that regulate appetite and glucose metabolism, while Tirzepatide combines GLP-1 and GIP receptor activation for dual-pathway metabolic support. Dr. Nafsi evaluates each patient's medical history, current pulmonary status, and weight loss goals before initiating peptide therapy. Patients receive guidance on injection technique, dosage titration schedules, and strategies to manage potential gastrointestinal side effects during the adjustment period. The clinic's respiratory therapists contribute to patient education, particularly for those managing both weight loss and chronic lung conditions simultaneously.
Dr. Nafsi's fellowship training in pulmonary and critical care medicine informs her approach to patient evaluation and treatment planning. Her FCCP designation indicates advanced expertise in chest medicine, a credential earned through rigorous examination and clinical experience requirements. The clinic's staff includes respiratory therapists who assist with pulmonary function testing, inhaler technique instruction, and patient education on disease management. For weight loss patients, the team provides ongoing monitoring of metabolic markers, medication tolerance, and progress toward individualized targets, with adjustments made based on clinical response rather than predetermined protocols.
Patients access Rockford Pulmonary Clinic services through telehealth consultations available to residents of Illinois and Wisconsin. Initial weight loss consultations involve a comprehensive review of medical history, current medications, previous weight loss attempts, and any contraindications to GLP-1 therapy such as personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Follow-up appointments track weight trends, assess medication tolerance, and address questions about nutrition, physical activity modifications, and managing expectations during weight plateaus. The clinic's telehealth model allows for flexible scheduling while maintaining regular provider contact throughout the treatment course.
The clinic's dual focus on pulmonary medicine and metabolic health creates a unique practice model in Rockford, where patients can address both respiratory conditions and weight management under one medical team. Pricing transparency for weight loss programs is discussed during initial consultations, with costs varying based on medication selection, dosage requirements, and insurance coverage. The clinic does not accept all insurance plans for weight loss services, and patients receive clear information about out-of-pocket expenses before beginning treatment. Dr. Nafsi's willingness to answer detailed questions about medication mechanisms, expected timelines, and realistic outcomes has been noted by patients, as has the staff's responsiveness to concerns that arise between scheduled appointments.
Tabassum Nafsi· MD FCCP
Tabassum Nafsi, MD FCCP
Pulmonologist
Dr. Nafsi is dedicated to providing compassionate, personalized care that puts the needs of patients first.
Topics Mentioned in Reviews
MyPeptideMatch.com is an independent directory. We do not provide medical advice. Always consult a qualified healthcare provider before starting any peptide therapy.


